Guggenheim Maintains Buy on Helus Pharma, Raises Price Target to $49

Benzinga · 2d ago
Guggenheim analyst Eddie Hickman maintains Helus Pharma (NASDAQ:HELP) with a Buy and raises the price target from $45 to $49.